---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336462"
form_type: "8-K"
ticker: "GENB"
cik: "0002100782"
company_name: "Generate Biomedicines, Inc."
filed_at: "2026-08-06T10:00:47+00:00"
generated_at: "2026-08-06T10:11:56.404411+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Generate Biomedicines Q2 net loss $67.3M; Phase 3 asthma studies advancing, cash $457.4M

## Summary
- Revenue $6.3M (down from $10.1M YoY); net loss $67.3M vs $56.7M YoY; cash $457.4M (down from $516.6M Q1).
- Phase 3 SOLAIRIA-1/2 for GB-0895 (anti-TSLP) in severe asthma recruiting in 33 countries; Phase 1b COPD data at ERS Sept 8.
- Phase 1 for GB-4362 (MMAE neutralizer) dosed first cohort; FDA Fast Track for urothelial cancer toxicity reduction.
- Novartis advanced a biologic designed with Generate's platform into preclinical pipeline; first AI-enabled biologic to reach this stage.
- GB-5267 CAR T Phase 1 recruiting for ovarian cancer; first patient expected in 2026; cash runway into H1 2028.

## SEC filing metadata
- accession: 0001193125-26-336462
- form_type: 8-K
- ticker: GENB
- cik: 0002100782
- company_name: Generate Biomedicines, Inc.
- filed_at: 2026-08-06T10:00:47+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2100782/000119312526336462/0001193125-26-336462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2100782/000119312526336462/ck0002100782-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336462
- JSON: https://secwatch.observer/filing/0001193125-26-336462.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.